The availability of complete genome sequences of many bacterial species is facilitating numerous computational approaches for understanding bacterial genomes. One of the major incentives behind the genome sequencing of many pathogenic bacteria is the desire to better understand their diversity and to develop new approaches for controlling human diseases caused by these microorganisms. This task has become even more urgent with the rapid evolution of antibiotic resistance among many bacterial pathogens. Novel drug targets are required in order to design new antimicrobials against antibiotic-resistant pathogens. The complete genome sequences of an ever increasing number of pathogenic microbes constitute an invaluable resource and provide lead information on potential drug targets. This review focuses on in silico analyses of microbial genomes, their host-specifi c adaptations, with specifi c reference to genome architecture, design, evolution, and trends in computational identifi cation of microbial drug targets. These trends underscore the utility of genomic data for systematic in silico drug target identifi cation in the post-genomic era.
Introduction
The science of genomics has largely been driven by the desire to understand the organization and function of genomes. The growing body of microbial genome sequences, accumulating rapidly in public databases, has advanced the fi eld of comparative genomics and is leading to new insights into how genomes change over time, how microbes cause disease and contribute to natural, environmental and biological processes. Lurking within the strings of letters are the details of the proteins and pathways that enable bacteria to metabolize numerous compounds, inhabit a diverse range of environments, infect other organisms and share genetic material [1] . Unraveling these details could potentially lead to the development of novel vaccines, the creation of useful antimicrobial compounds, and the design of innovative strategies to modify bacteria for applications such as bioremediation [2] [3] [4] . Comparative in silico methods, along with large-scale approaches such as transcriptomics and proteomics, are beginning to reveal insights into new virulence genes, host-pathogen interactions, and the molecular bases of host specifi city. Sequence data are also accumulating from multiple isolates or strains of a single pathogen, and these data have proven to be valuable in providing new insights into the genetic variability that is present in a particular species as well as in facilitating correlations between genotype and phenotype. This review will focus on in silico analyses of microbial genomes, their host-specifi c adaptations, with specifi c reference to genome architecture, design, evolution, and trends in computational identifi cation of microbial drug targets.
Genomics in genome design and diversity
Bacteria generally have double-stranded circular DNA chromosomes. However, a number of species have been shown to have linear chromosome [5] . The best known example is Borrelia burgdorferi, which also has largest number of extrachromosomal elements, i.e. 12 linear and 9 circular plasmids [6, 7] . Unlike other bacteria, Vibrio cholerae and Deinococcus radiodurans have two circular chromosomes per cell. The genome sizes for completely sequenced bacterial genomes vary from 0.49 Mb (Nanoarchaeum equitans) to 9. 
Genomics in understanding host-specifi c adaptations and genome evolution
One of the insights to emerge from bacterial sequencing and comparative genomics is that the bacterial genome is a dynamic entity shaped by multiple forces including genome reduction, genome rearrangement, gene duplication, gene loss and gene acquisition by lateral gene transfer [8] . An interesting group that has been targeted for genome analysis represents species that are no longer free-living, are mostly pathogenic, and are now dependent on their hosts for survival because of genome reduction, i.e. the obligatory intracellular parasites [9] . These microbes serve as an excellent model to study how bacteria exploit the functions of their host cells. Despite their similarity in biology and reduced genome size (<2 Mbp), these species display extreme diversity in tissue tropism and disease expression that hitherto remain a major unanswered question in microbial behavior.
There have been reports on the evolution of these bacteria from larger genomes through genome deterioration that have provided examples of reductive convergent evolution in the genomes of Rickettsia prowazekii and Chlamydia trachomatis, and have associated this phenomenon with metabolic parasitism in response to intracellular habitat [10, 11] . Sakharkar et al [12] reported that throughout evolution, genes that once played major roles are eventually discarded because they are no longer under selective pressure. Genome stability is therefore achieved by the loss of selected groups of proteins involved in genome dynamics and gene mobility [12] . Gene degradation targets overlapping subsets of potentially dispensable genes while adapting to the selective pressures of different niches [13] . Therefore, genes found as multiple copies may outline their specifi c adaptations [14] . The higher proportion of intergenic DNA may be scattered remnants of genes lost in a stepwise process [15] [16] [17] [18] . Andersson et al [15] have shown in Rickettsia that deletions are far more common than insertions, and on the average much larger in size. They speculated that once a rickettsial gene becomes non-functional, it will be eliminated from the genome solely by mutational events.
In efforts to characterize the evolutionary forces underlying genome reduction and to understand the dynamics of microbial genomes, a critical issue concerns the size, content and processes of deletions [12] . The reduction in genome size of obligatory intracellular parasites results in genome stability via loss of selected groups of proteins, e.g. loss of prophage component proteins. These proteins are mainly involved in genome dynamics as well as gene mobility, and loss of these proteins decreases the rate of gene rearrangement, which is a requirement for an obligatory intracellular life-style. In most of the microorganisms studied, there is maximum reduction in the number of genes encoding proteins of 200-600 amino acids in length (Fig. 2) . A manual survey indicated that most of the proteins in this range are metabolic enzymes. Interestingly, although Mycobacterium leprae and Coxiella burnetii ostensibly show similar trends, the extent of reduction is less in these bacteria. Both these genomes have been reported as "genomes in decay", particularly in terms of the presence of mobile elements, pseudogenes, extent of genome reduction, metabolic capabilities, and transporter profi les. Despite being more than 800 amino acids long, enzymes categorized as housekeeping and that account for essential requirements including DNA replication, repair, transcription and translation (e.g. RNA polymerase, gyrase, exonuclease) are not lost in any of the obligatory intracellular parasites. Both long and short proteins of all prokaryotes are functionally important in their own right, and bacteria selectively lose genes based on their environmental niche. These analyses may shed light on the backbone genome and differential loss of genes in response to bacterial life-style. Knowledge in this domain may contribute to elucidating the fundamental mechanisms of host-pathogen interactions, with specifi c reference to the recognition of determinants responsible for host specifi city, virulence, disease pathogenesis, and to the identifi cation of new targets for vaccine and drug design.
Genomics and antibacterial targets
Recent advances in genomics have provided an opportunity to expand the range of potential drug targets and have facilitated a fundamental shift from direct antimicrobial screening programs towards rational target-based strategies [19] . Until recently, the major barrier to target-based screening was the small number of potential targets limited by the number of cloned and characterized genes. This barrier has in effect been removed as a consequence of the comprehensive genome sequencing projects which make available all genes in ~300 completely sequenced microbial genomes as potential targets for prioritization on the basis of various user-defi ned criteria (http://www.ncbi.nlm.nih.gov/ genomes/lproks.cgi). Genomics can be applied to evaluate the suitability of potential targets using two criteria, i.e. "essentiality" and "selectivity" (Fig. 3) [20] . The target must be essential for the growth, replication, viability or survival of the microorganism, i.e. encoded by genes critical for pathogenic life-stages. The microbial target for treatment should not have any well-conserved homolog in the host, in order to address cytotoxicity issues. This would help to avoid expensive dead-ends when a lead target is identifi ed and investigated in great detail only to discover at a later stage that all its inhibitors are invariably toxic to the host. Genes that are conserved in different genomes often turn out to be essential [21] [22] [23] [24] . A gene is deemed to be essential, if the cell cannot tolerate its inactivation by mutation, and its status is confi rmed using conditional lethal mutants.
An interesting approach to the prediction of potential drug targets, designated "differential genome display" has been proposed [25, 26] . This approach relies on the fact that genomes of parasitic microorganisms are generally much smaller and code for fewer proteins than the genomes of free-living organisms. The genes that are present in the genome of a parasitic bacterium, but absent in the genome of a closely related free-living bacterium, are therefore likely to be important for pathogenicity and can be considered candidate drug targets. Galperin and Koonin [27] suggested searching for drug targets among previously characterized proteins that are specifi c and essential for a particular pathogen (Fig. 3) . Sakharkar et al [20] used three-way genome comparisons to identify essential genes in Pseudomonas aeruginosa. There analyses identifi ed 306 essential genes that may be considered as potential drug targets in P. aeruginosa. The resultant analyses are in good agreement with the results of systematic gene deletion experiments [20] . Recently, the potential of the products of fusion genes as putative microbial drug targets was reported (Fig. 3) [28] . Thus, the use of these simple conservation and exclusion rules offers a powerful mechanism for identifying candidate target genes across any set of genomes.
Generally, another essential requirement of a target is an understanding of the function of the gene product, ideally at the level of its biochemical activity and pathway involved. Transcript profi ling using DNA microarrays provides a method for high throughout analyses of gene expression at the level of the whole genome [29] . This can offer clues to previously uncharacterized genes as well as provide information on cellular responses to treatments with small inhibitor molecules. This information is critical for drug discovery and development [30] . Identifi cation of the targets and pathways affected by known antimicrobials should provide the basis for rational modifi cation of existing compounds and the selection of new pathways. Transcriptional co-regulation may indicate physical or functional interactions between proteins. Protein profi ling provides a complementary approach to DNA microarrays, and aids in the investigation of the total protein content of a cell and its response to changing conditions. Thus, new technologies based on microbial genomics have generated increasingly effi cient drug discovery programs.
Has genomics delivered?
The synergy between genomics and genetics has definitely identifi ed and delivered novel essential targets for target-based discovery efforts. In cases such as obligate intracellular bacteria and species that cannot be cultured in vitro, genomics has played a dominant role in the effi cient discovery of virulence genes and leads for vaccine design [31] . Genomics has delivered information regarding the overall conservation and species specifi city of genes, and hence their therapeutic potential as antimicrobial targets (broad and narrow spectrum), in addition to information on their potential cytotoxicity. Genomics has helped us understand genome evolution and adaptation. The importance of genomic sequences is best illustrated by pathogens that are diffi cult to grow in vitro and have poorly characterized genetic systems, e.g. obligatory intracellular parasites. Genome sequence data have the potential to deliver rapid and highly species-specifi c DNA probes and immuno-probes for the identifi cation of pathogens. Genomics has provided the impetus to develop and implement new techniques to manage and exploit this sequence information leading to the creation of a new generation of "omics" offsprings, which emphasize comparative and functional aspects of genomics, transcriptomics, proteomics, metabolomics, infectomics, pharmacogenomics, immunoproteomics, and importantly "econ-omics". Genomics has given birth to metagenomics, and has also stimulated the development of improved cultivation techniques [32]. However, major challenges remain as these "omics" often stand in isolation. There is a need to pull them together to gain an understanding of microbiology at a higher level, with its complex collection of networks and pathways. Thus far, studies on microbial genomics have only scratched the surface of microbial diversity and have revealed how little is known about microbial species. The imminent deluge of microbial sequence data represents new opportunities for future research and potential biological resources to be explored and exploited. A major stumbling block in the genomics revolution has been the large number of genes with unknown function that have been identifi ed in every organism sequenced to date. Almost half of the ORFs in each species are of unknown biological function. When the functions of this large subset of genes begin to be explained, it is likely that entirely novel biochemical pathways will be identifi ed that may be relevant to medicine and biotechnology. It is imperative not only to improve annotation quality but also to dovetail computational approaches with empirical studies, especially those that seek to unravel the functions of the numerous hypothetical genes still found in genomes. Understanding the plasticity of bacterial genomes will shed light on their transformability. Thus, translating genomics to functional genomics is a major bottleneck in the path towards greater success for microbial genomics and its applications for human health. Nonetheless, it is clear that microbial genomics will drive a new era of therapeutic discovery in the near future. 
